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Abstract 
Helicobacter pylori (H. pylori) is a bacterium that selectively colonizes gastric epithelium in more 
than 50% people over the world. The infection is usually acquired in early childhood and rarely 
resolved spontaneously; transmission is mostly person to person, and occurs by fecal-oral or oral-
oral modality. Diagnosis and antibiotic treatment may lead to eradication of H. pylori, improving 
the prevention and the outcome of gastric and extragastric diseases. Many tests are currently 
available for the diagnosis of H. pylori infection and the choice depends on several clinical aspects 
including symptoms, age, indications for testing, concomitant medications and comorbidities. 
Invasive tests (i.e. endoscopy with histologic assessment) are considered the gold standard, but they 
are expensive and should be performed only in an appropriate context. The most common non-
invasive tests are urea breath test (UBT), stool antigens test and serology. UBT is non-invasive, 
quick, safe, accurate and cheap. This test is performed mainly with 13C and is based on the presence 
of H. pylori urease, an enzyme that converts urea (labelled with an isotope) into CO2. Labelled CO2 
is then exhaled and measured by dedicated spectrophotometers. This review analyses with special 
emphasis UBT, focusing on its molecular aspects.  
 
Key words: breath test; diagnosis; Helicobacter; urease. 
 
 
3 
 
Helicobacter pylori (H. pylori) is a spiral shape Gram-negative bacterium, discovered in 1982 by 
Marshall and Warren,1 that selectively colonizes gastric epithelium (mainly the antrum) of more 
than 50% people over the world.2 Phylogenetic analysis pointed out that H. pylori global spreading 
occurred from East Africa to other continents thousands of years ago.2,3H. pylori infection is usually 
acquired in early childhood and the risk declines sharply after 5 years of age. The higher prevalence 
in older age groups is thought to reflect a cohort-effect related to poorer living conditions during 
childhood.4,5  
Unless antibiotic therapy for eradication is administered, infection persists and could lead to 
chronic gastritis and peptic ulcer (PU).6 Because of the well-known association with gastric cancer 
(GC) and mucosa-associated lymphoid tissue (MALT) lymphoma, the World Health Organization 
(WHO) has categorized H. pylori as a group I carcinogen.7-8 H. pylori infection has also been 
related to several extra-gastric diseases, especially those of autoimmune origin, attracting the 
attention of researchers.9 Hundreds of diseases have been investigated for a possible relationship, 
but only for a few the association was precisely demonstrated (i.e. iron deficiency anemia, vitamin 
B12 deficit and idiopathic thrombocytopenic purpura), although the exact causative mechanisms 
remain unexplained. In this context, the prevailing idea is that H. pylori is not an etiologic agent but 
it acts as environmental trigger in genetically predisposed subjects. However, these suggestions are 
supported by small data and evidence is still lacking.10-15 Nonetheless, H. pylori infection has been 
inversely associated to different rates of asthma and allergies.16 
 Currently, H. pylori prevalence is still high, showing different rates worldwide: in Europe it 
is lower in Northern countries (ranging from 31.7% among blood donors in Netherlands to 84.2% in 
Portugal). In North America, rates are similar to Europe, while the prevalence is higher in Central 
and South America, and in Asia, ranges from 54% to 72%.17 Some studies conducted in Africa 
reported a prevalence of infection between 65.7% and 75.5%, with a significant increase with age.5 
The principal risk factors for H. pylori infection are represented by low socioeconomic 
status (risk of contamination), poor health and crowded living conditions, attendance of children at 
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day care centres. In low income countries, additional factors can be represented by drinking spring 
water and vegetarian diet.5 Regarding the route of transmission, it is mostly person to person, and 
occurred by fecal-oral or oral-oral way.7 
Due to the increasing rate of antibiotic resistance, reported by a European multinational 
study, the optimal regimen to cure H. pylori infection should be decided regionally. 18 The 
Maastricht V/Florence Consensus Report19 and the American College of Gastroenterology Clinical 
Management Guideline20 highlight that in countries with low clarithromycin resistance rates (<15-
20%), an empiric clarithromycin-based regimen can be used. In countries with high clarithromycin 
resistance rates or, in the American Guideline,20 with a previous exposure to clarithromycin, a 
bismuth-containing quadruple therapy (with metronidazole and tetracycline) is the first choice. In 
case of persistent infection, after a previous clarithromycin-containing regimen, this drug should be 
avoided in second line therapy. Options after initial eradication failure include tailored therapy 
(choosing antibiotic combinations based on antibiotic susceptibility testing), empiric bismuth-
containing quadruple therapy or triple levofloxacin-based therapy. Encouraging data are reported, 
both for the first-line and for rescue treatments, with the use of a formulation of bismuth subcitrate 
potassium, metronidazole, and tetracycline contained in a single capsule, together with a PPI.21,22 
Rifabutin- and furazolidone-based regimens should also be considered in rescue regimens.23 
 
                                            Helicobacter pylori: colonization and survival 
H. pylori has an impressive ability to persist chronically in the human stomach.3,24,25 An essential 
step in the colonization of gastric epithelium by the bacterium is mediated by outer membrane 
proteins (OMPs) that serve as adhesion molecules. Most of H. pylori OMPs play a role in 
adherence, associated with elevated gastric epithelial cell damage risk and, possibly, involved in the 
pathogenesis of GC. H. pylori genome has more than 30 genes which encode for OMPs, that can be 
divided into Helicobacter outer membrane proteins (Hop) subgroups.26-29 Some of these proteins 
have been identified. Blood group antigen binding adhesin (BabA), the first discovered, is involved 
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in binding with ABO group (Lewis antigen, expressed in stomach) and leads to the synthesis of pro-
inflammatory cytokines. Sialic acid binding adhesin (SabA) is used for binding to sialyl-dimeric-
Lewis, a receptor for H. pylori whose expression increases in the early infection and is closely 
associated with gastric atrophy, intestinal metaplasia (IM) and GC development. Also, adherence 
associated lipoproteins (AlpA/B) are two homologous proteins involved in bacterium adhesion, 
though the receptor is still undetermined. HopZ is another bacterial adhesin with an unknown 
receptor and is regulated by contact with gastric cells and by the pH of gastric environment. The 
outer inflammatory protein (OipA) is encoded by HopH gene and induces interleukin (IL)-8 
production promoting inflammation; it correlates with severe outcomes such as duodenal ulcer and 
GC.1,28,30  
In addition, several factors play an important role independently of bacterial interactions 
with epithelium. Indeed, during colonization, only 20% of the bacteria interact with the epithelium. 
Cag pathogenicity island (Cag PAI) consists of a cluster of 31 genes, most of them coding for a 
T4SS, a needle-like structure that penetrates the epithelial cell membrane and allow H. pylori 
translocation into the cells. Cytotoxin-associated gene A (CagA) protein is an effector protein of 
125 and 140 kDa, encoded in CagPAI with no homologous in other bacteria. It is the most virulent 
factor and a risk factor for PU and GC. In the epithelial cell, CagA initiates signalling events 
through tyrosine phosphorylation in the Glu-Pro-Ile-Tyr-Ala (EPIYA) domains (with different 
motifs in different strains). Moreover, peptidoglycan is recognised by the nucleotide-binding 
oligomerization domain-containing protein 1 (NOD1), a pathogen-associated molecular pattern 
(PAMP) that induces nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) 
pathway and up-regulation of pro-inflammatory response. There are other Cag proteins, such as 
CagL, CagY, CagI, all important for H. pylori colonization and under investigation for their 
potential use in the development of an effective vaccine. CagA is also known as the first bacterial 
onco-protein, ranking the H. pylori-mediated adenocarcinoma as the second for cancer mortality 
worldwide.31 Further studies are needed on CagA fragmentation in vivo, in order to understand 
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CagA translocation into cytosol, its interaction with cellular proteins and neoplastic transformation 
of the infected cells.32,33 
The vacuole-inducing toxin (VacA), contributes to the binding of the bacterium to the gastric 
epithelium and plays a key role in cell vacuolization, characterized by the accumulation of large 
vesicles that possess hallmarks of both late endosomes and early lysosomes. Moreover, VacA leads 
to mitochondrial disfunction and blocks T-cell activation, modulating immune response to the 
infection.34,35 
 The high temperature requirement A (HtrA) has a serine-protease enzymatic activity and 
cleaves, for example, E-caderin, contributing to disruption of cellular junctions. HtrA disrupts 
epithelial barrier and allows to H. pylori to invade the intercellular space. In addition, the E-
cadherin ectodomain released is a key prognostic indicator in GC.32 
Once H. pylori is ensconced in the mucus it is able to fight the stomach acid by the 
production of the enzyme urease. Thus, urease has a key role in the survival of H. pylori. Since the 
translational relevance of the knowledge of urease is the main aim of this review it will be discussed 
in the appropriate section.   
  
                                                    Helicobacter pylori: diagnosis 
The methods to diagnose H. pylori infection can be classified as invasive or non-invasive, the 
former being based on biopsy specimens obtained at endoscopy. The choice of the test depends on 
the clinical context. When a patient needs an upper gastrointestinal (GI) endoscopy, due to alarming 
symptoms or older age (generally >45 years, but age should be determined locally according to GC 
risk), H. pylori infection can be detected by an invasive test, in the remaining cases a non-invasive 
test is more appropriate.36-39 
 
Non-invasive tests 
Non-invasive tests are mostly used and reported. According to Maastricht V/Florence Consensus 
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Report, urea breath test (UBT) is the recommended non-invasive test in the context of a “test-and-
treat” strategy. Monoclonal stool antigens test (SAT) could be used as an alternative method. Proton 
pump inhibitors (PPI) should be discontinued at least 2 weeks before testing, while bismuth and 
antibiotics should be discontinued 4 weeks earlier.19 Furthermore, SAT and UBT cannot be used for 
patients suffering from ulcer bleeding.40 Serological tests can be used only after validation; 
conversely, rapid serology tests using whole blood should be avoided.19 In Eastern Asia (such as 
Japan and South Korea), immunoglobulin (Ig)G serological detection is recommended as one of the 
preferred methods for the initial diagnosis.41 It is necessary, in every country, to validate H. pylori 
detection kits used for that specific population. The performances of the serological kits may be 
affected by antibody response (IgG or IgA), age, gender, health status and ethnicity of the host.42,43  
For serologic testing only IgG detection is considered, since H. pylori infection is chronic; the 
preferred method is the enzyme-linked immunosorbent assay (ELISA), with overall sensitivity and 
specificity of 85% and 79%, respectively. However, there is a marked variability in accuracy 
according to the kits available and this test cannot be used to confirm H. pylori eradication, since 
after-treatment seronegativity may take months or even years. Then, serology should be considered 
when other diagnostic tests could be falsely negative, such as in patients with bleeding ulcers, 
gastric atrophy or recent use of PPI and antibiotics.19,44,45 
UBT and SAT are very specific (>90%), while H. pylori IgG can persist for years and a 
positive test can indicate both a present or a previous infection. After unsuccessful treatment, 
culture and antimicrobial sensitivity testing may help to determine an appropriate treatment 
regimen.46  
 
Invasive tests 
Conventional endoscopic exam is usually performed to diagnose H. pylori-associated diseases. 
Moreover, it is useful to obtain tissue samples for further tests, including rapid urease test (RUT), 
histology, culture and molecular biology methods. Gastric biopsy is usually obtained from the 
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antrum, but greater curve sampling is suggested for patients with antral atrophy or IM to avoid false 
negative results.47 In case of clinical indication for endoscopy and no contraindications for biopsy, 
RUT should be the first-line test for the diagnosis of H. pylori infection; to note, this test is not 
indicated for assessment of the eradication of the bacterium. Several commercial rapid urease tests 
exist, such as gel-based tests (24-hours CLOtest, HpFast), paper-based tests (1-hour PyloriTek, 
ProntoDry) and liquid-based tests (5-minutes UFT300, EndoscHp). These tests have specificity 
above 95%-100% and sensitivity above 85%-95%. Bleeding makes RUT significantly less reliable 
test than other tests.28,47,48 
 Histologic assessment is considered the gold standard for the direct detection of H. pylori, 
but can be influenced by site, size, number of biopsies, staining methods, use of PPI or antibiotics 
and pathologist experience. Immunohistochemical stain is the most sensitive and specific approach, 
but in most cases hematoxylin-eosin stain is sufficient for the diagnosis. Other stains and/or 
immunohistochemical testing of H. pylori can be used as ancillary tests, only if histology is not 
normal.47 
Fluorescent in-situ hybridization using peptide nucleic acid probes (PNA-FISH) method is 
useful for the diagnosis of infection and to assess clarithromycin resistance of H. pylori.49 New tests 
have been developed, such as polymerase chain reaction (PCR)-based Amplidiag H. pylori test, for 
the detection of clarythromicin resistance, since adapted therapy increases eradication rates.50 
 
                       From urease to UBT: An example of translational medicine 
Since the human stomach is an unfriendly place, to overcome the barrier represented by its acidic 
environment (pH < 2), H. pylori produces a large amount of the nickel (Ni)-containing enzyme 
urease, which provokes the breakdown of urea (of which there is an abundant supply in the stomach 
originated from saliva and gastric juices) with production of the cell-toxic ammonia in the gastric 
epithelium. After exit from the bacterial cell, ammonium neutralizes the acidity and creates a nearly 
neutral microenvironment for H. pylori survival. This phenomenon allows the bacterium to safely 
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cross the mucus layer to the epithelium surface.3,51 Urease represents 10% of total proteins among 
those expressed by H. pylori. Urease is found both inside and outside the bacterium. The relative 
contributions of these ureases are determined both by their respective amounts and the pH of the 
medium. At acidic pH of 4.5 or less, the outer urease is inactive; therefore, it does not contribute to 
survival from acid. The inner urease, however, shows 10-20 folds increase in activity when external 
urease is present but it rises much more if the latter is inactivated. At least seven gene products of 
this pathogen are required for the catalytic urease activity. UreA is a species-specific gene present in 
all strains of H. pylori. While ureA and ureB encode for the two structural subunits that constitute 
the apoenzyme,52-54 the other five genes (ureE, ureF, ureG, ureH and ureI) encode for accessory 
proteins involved in the incorporation of Ni ions, crucial for the activation of the urease system, into 
the apoenzyme.3 One active urease molecule requires 24 Ni ions for full enzymatic action. After 
entering the outer membrane, the Ni molecules are transported to the cytoplasm through the protein 
channel NixA, a monomeric high-affinity Ni-uptake protein localized in the cytoplasmic (inner) 
membrane of the bacteria. 3 NixA deletion mutants still retained urease activity to some extent (up to 
50% in some strains), indicating the existence of an alternative Ni transporter.55 A reported Ni 
transport system, required for Ni-dependent urease activation and acid survival, is the gastric 
Helicobacter species-specific NiuBDE.56 Another type of Ni-uptake strategy requires the multiple-
component ATP-binding cassette (ABC)-transporter operon consisting of four genes (abcABCD), 
and which is potentially involved in NixA-independent Ni uptake.57 Insertional mutagenesis in 
nixA, abcC or abcD genes significantly reduce urease activity (42-72%), whereas abolition of 
urease activity is achieved by double mutations in both nixA and abcC genes.58 
The intra-bacterial concentration of Ni ions is well regulated. Too low amount of Ni entry 
impairs urease activity and acid survival, while too much amount of Ni entry generates reactive 
oxygen species leading to cell damage. A family of DNA binding Ni-responsive regulatory protein 
(NikR) regulates the Ni-responsive genes including ureA, ureB, nixA, frpB4, and fecA3.3 
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The role of UreI-mediated urea transport is crucial in the control of urease and in handling 
excess NH3. It is based on an integral cytoplasmic membrane protein that might form a urea-
specific pore, controlled by external pH via a shift in periplasmic pH. As the external pH drops, 
UreaI opens up allowing urea to reach cytoplasmic urease, that neutralizes the acid; as the pH 
approaches neutrality, the enzyme is denied access to the substrate to avoid excessive NH3 
production.59  
The knowledge of urease’s activity has been the basis for the development of UBT. This is a 
semiquantitative accurate test with high sensitivity and specificity. It is a direct method able to 
detect the active H. pylori infection, assessing the whole stomach and avoiding sampling errors. 
Patient should be fasting (for at least 6-8 hours before the test) and off medications for 4 weeks; no 
further precautions are required.59,60 It is important to report demographics, indication for the study 
(i.e. suspected H. pylori infection, follow-up after eradicating therapy), the procedure (i.e. 
radiopharmaceutical and dosage, number and timing of breath samples collected), result (i.e. 
disintegrations per minute in each sample), reference ranges, study limitations, confounding factors 
and interpretation (i.e. positive, negative, indeterminate).60,61 
Main causes of potential false-negative results are concomitant medications, in particular 
with antibiotics, bismuth, sucralfate and PPI. Moreover, false-negative results can be due to non-
fasting, gastric surgery and difficulty with swallowing (additional breath samples may be helpful).62 
False positive results may be related to oropharyngeal bacteria, if breath samples are taken within 
10-15 minutes of swallowing the isotope, gastric surgery with potential resultant bacterial 
overgrowth (non-H. pylori urease) and achlorhydria.62 
It is possible to perform the test using either 13C or 14C. The former is a nonradioactive 
isotope of carbon that is measured by isotope-ratio mass spectrometry. 14C is a radioactive isotope 
of carbon that is measured by a scintillation counter, a pure beta-emitter with a physical half-life of 
5730 years and maximum energy of keV.60 
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In the standard procedure, a breath sample is collected at baseline and 30 minutes, 
respectively, after drinking a 100 mg dose of 13C-labeled urea with 1.2 g of citric acid in 100 ml of 
water.62,63 The UBT relies on the ability of H. pylori urease to convert into carbon dioxide (CO2) the 
urea that has been labelled with isotopes and then ingested by the patient. The converted labeled 
CO2 diffuses across the epithelial cells, is conveyed by the bloodstream and ultimately is exhaled by 
the lungs. A breath sample from the patient is finally collected to measure the amount of labeled 
CO2 exhaled and thus the presence or absence of H. pylori infection (Figure 1).
62-65 The difference 
in CO2 levels between the baseline breath sample (before ingestion of labelled urea) and the post-
administration breath sample can be detected by a specific mass spectrometer or infrared 
spectrophotometer. Balloons with breath samples can be shipped to another laboratory.62 Since 13C-
urea is a non-radioactive isotope, samples can be easily sent for analysis to a central laboratory; 
thus, 13C-UBT can be performed also in outpatient clinics.62Samples are analyzed for the 13C/12C 
ratio with a mass spectrometer. Results are expressed as excess δ13CO2 excretion per ml, which 
represents 13C enrichment over and above the baseline sample.64,66 
 Several modified versions have been proposed (Table I). For example, the patient swallows 
the 14C urea in a capsule form containing 1 mg urea, labelled with 37 kBq, with 20 ml tepid water. 
At 3 minutes post-dose, the patient drinks another 20 ml tepid water; 7 minutes later, the patient is 
asked to take a deep breath, hold it for 5-10 seconds and then exhale through a straw into a mylar 
balloon. Another optional breath sample can be obtained at 15 min post-dose using another 
balloon.60 Ferwana et al. compared 13C and 14C UBT; both demonstrated high performance against 
the gold standard test without a significant difference: sensitivity 0.96 (95%Confidence Interval 
[CI]: 0.95-0.97), specificity 0.93 (95%CI: 0.91-0.94).67 
Low dose UBT has been proposed since 2002, in this case 50 mg 13C-urea using a simple 
test meal and a 15 min sampling interval appeared cost-effective and convenient. Using a low cut-
off (2.5‰), no loss of diagnostic accuracy was observed, with high sensitivity (99.1%) and 
specificity (97.3%).68 Low dose UBT with 50 mg tablet (instead of 75 mg) was proposed by Mattar 
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et al. The relative sensitivity of 13C-urea with capsule was 100% at 20 minutes and 88% at 10 and at 
30 minutes. The relative specificity was 100% at all-time intervals. Among 83 patients that 
underwent capsule breath test and endoscopy the capsule breath test presented 100% of sensitivity 
and specificity.69 Low dose UBT with 25 mg tablet does not reach sufficient accuracy and, although 
the data are controversial,70 at the moment, is not recommended.71 Nawacki et al. compared UBT 
with RUT collected during endoscopy in a group of 50 patients: consistency of the results of both 
tests was 96%. The only discrepancy concerned two women with grade 1 changes in gastroscopy.72  
Tepeš et al. investigated a modified UBT in patients taking PPI using 13C test meal Refex. Using a 
cut off 2.5‰, sensitivity was 92.45% by per-protocol (PP) analysis and 78.13% (95%CI: 66.03%-
87.49%) by intention-to-treat (ITT) analysis. Specificity was 96.00% in the ITT population and 
97.96% in the PP population (95%CI: 89.15%-99.95%). In conclusion, this new test meal based 
13C-UBT is highly accurate in patients on PPIs and can be used in those unable to stop their PPI 
treatment.73 Gilardi et al. analysed the accuracy of BreathID®, a device with continuous breath test 
sample collection and analysis after labelled urea intake. This approach was compared with the 
classical method. Correlation between the two methods was excellent with a Cohen’s k=1.00. 
Furthermore, using a visual analogue scale, the authors showed that BreathID® had a significant 
greater acceptance.74 
In preschool children, cut off value may be adjusted to reduce false positive results, that are 
10 times higher in children aged 6 years old or less. The reasons could be ascribed for instance to 
urease-producing microorganisms in the oral cavity of young children or increase production of 
CO2. Optimal cut-off value could be 4‰ for children older than 6 years old and 7‰ for children 
younger than 6 years old.4 
 The use of an indeterminate zone of result values (for example 2.5-3.5‰) may help to 
improve the diagnostic accuracy of the test, in order to minimize false-positive and false-negative 
results.64 
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Conclusions 
Breath tests are commonly used in several clinical settings.75,76 For the diagnosis of H. pylori 
infection, UBT is quick, safe, accurate and requires very few precautions when the isotope 13C is 
used. Adjustment of the cut-off value or modified versions of UBT may be helpful in special 
settings, such as young patients or those who cannot stop PPI treatment. 
In conclusion, the use of UBT in clinical practice represents a model of translational 
medicine, beginning from the knowledge of H. pylori urease and ending in the easy and cheap 
diagnostic application.   
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Table I.-Main studies assessing sensitivity and specificity of urea breath test (UBT) 
Name Year Se (%) Sp (%) Isotope Cut-off Note 
Liao et al. 2002 99.1 97.3 13C 2.5‰ 50 mg 
Coelho et al. 2011 83.5 99.4  13C 4‰ 25 mg vs 75 mg 
Mattar et al. 2014 100 100 13C 4‰ 50 mg vs 75 mg 
Tepes et al. 2017 92.5 96.00  13C 2.5‰ PPI treatment 
Nawacki et al. 2018 88.9 87.5  13C 5‰ UBT vs Biopsy 
Se: sensitivity; Sp: specificity; PPI: proton pump inhibitors 
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Figure 1.- Principle of the urea breath test 
 
